| Literature DB >> 35433102 |
Elisa Troiano1,2, Tiziano Giacché1,2, Andrea Facchini1,2, Nicholas Crippa Orlandi1,2, Matteo Cacioppo1,2, Marco Saviori1,2, Vanna Bottai3, Francesco Muratori4, Nicola Mondanelli1,2, Stefano Giannotti1,2.
Abstract
Introduction: An increasing number of patients is annually undergoing total hip arthroplasty (THA), and a significant proportion of these patients are elderly and consequently at a higher risk of complications because of age, osteoporosis, and medical comorbidities. Periprosthetic femoral fractures (PFFs) are one of the worst complications of THA associated with high rates of unfavorable prognosis. Besides, in the last decade, a new independent disease entity called "atypical femoral fracture" (AFF) has been identified and defined by the American Society for Bone and Mineral Research (ASBMR) task force. Some PFFs present clinical history and radiographic aspect consistent with an AFF, meeting the ASBMR criteria for the diagnosis of AFF except that PFFs by themselves are an exclusion criterion for AFF. However, there is an increasing number of published studies suggesting that periprosthetic atypical femoral fractures (PAFFs) exist and should not be excluded by definition. Significance: Nowadays, although there is an increasing interest in PAFFs, there are still very few studies published on the topic and a lack of consensus regarding their treatment. This narrative literature review aims to introduce this new emerging topic to a wider readership describing the characteristics of PAFFs and the state-of-the-art in their management. Conclusions: Many authors agree that PAFFs should be considered as a subgroup of PFFs that have atypical characteristics; they also show a significant correlation with prolonged bisphosphonate use. A correct diagnosis is paramount for proper treatment of the disease that requires both surgical and medical actions to be taken.Entities:
Keywords: AFF; PAFF; Teriparatide; incomplete fracture; insufficiency fracture
Year: 2022 PMID: 35433102 PMCID: PMC9006379 DOI: 10.1177/21514593221090392
Source DB: PubMed Journal: Geriatr Orthop Surg Rehabil ISSN: 2151-4585
ASBMR Task Force criteria to define an AFF.
| ASBMR Task Force Criteria to Define an AFF | |
|---|---|
| Mandatory criterion | |
| — | Fracture must be located along the femoral diaphysis between the lesser trochanter and the supracondylar flare |
| Major criteria (4 out of 5 must be present) | |
| — | The fracture is associated with no or minimal trauma |
| The fracture line originates at the lateral cortex and it is substantially transverse or short oblique | |
| An incomplete fracture involves only the lateral cortex, while complete fracture extends through both cortices and may be associated with a medial spike | |
| The fracture is noncomminuted or minimally comminuted | |
| Presence of localized periosteal or endosteal thickening (“beaking” or “flaring”) of the lateral cortex at fracture site | |
| Minor criteria (not necessary, sometimes associated with AFFs) | |
| — | Generalized increase in cortical thickness of the femoral diaphysis |
| Unilateral or bilateral prodromal symptoms (dull or aching pain in the groin or thigh) | |
| Bilateral incomplete or complete femoral diaphyseal fractures | |
| Delayed healing of the fracture | |
| Exclusion criteria | |
| — | Fracture of the femoral head and neck |
| Intertrochanteric fracture with spiral subtrochanteric extension | |
| Periprosthetic femoral fractures
| |
| Pathological fractures associated with primary or metastatic bone tumors and with miscellaneous bone diseases (Paget’s disease, fibrous dysplasia) | |
| Removed minor criteria with 2014 revision | |
| — | Some diseases: hypovitaminosis D, autoimmune diseases (such as RA), endocrinologic diseases (such as hypoparathyroidism)
|
| Assumption of some drugs (BPs, GCs, proton-pump inhibitors)
| |
aevidence now exists that PAFFs can occur.
bsome evidence exists that they are at least a risk factor for AFFs.
Suggested “short” panel for studying phosphocalcic metabolism. ALP: alkaline phosphatase, Ca: calcium, P: phosphorus, PTH: Parathyroid hormone, CTX: C‐telopeptide of type I collagen, P1NP: aminoterminal pro-peptide of type I procollagen, 25 (OH)D: cholecalciferol (vitamin D3).
| Suggested “Short” Panel for Phosphocalcic metabolism |
|---|
| ALP, U/L (range 55–142) |
| Ca, mg/dL (range 8.9–10.1) |
| P, mg/dL (range 2.5–4.5) |
| PTH, pg/mL (range 15–65) |
| CTX, ng/L (range 100–700, over 50 years) |
| P1NP, μg/L (range 15–75, over 50 years) |
| 25(OH)D, ng/mL (range 30–100) |
| Creatinine, mg/dL (range .6–1.1) |
Figure 1.Algorithm of treatment for PAFFs.
Figure 2.A transverse radiolucency line is visible on the lateral cortex. This is an incomplete PAFF, that may eventually progress to complete.
Figure 3.A complete PAFF clear of the stem (Vancouver type C).